For the year ending 2025-12-31, OM had -$88,508K decrease in cash & cash equivalents over the period. -$47,125K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -81,653 |
| Stock-based compensation expense | 15,616 |
| Depreciation and amortization | 4,341 |
| Non-cash lease expense | 1,583 |
| Non-cash interest expense | 2,758 |
| Amortization of premium on investments, net | 2,253 |
| Change in provision for inventories | -124 |
| Change in provision for credit losses | 3,515 |
| Loss on disposal of property and equipment | -5 |
| Loss on extinguishment of term loan | -7,685 |
| Accounts receivable | -3,775 |
| Inventories | -11,793 |
| Prepaid expenses and other assets | 940 |
| Accounts payable | -3,293 |
| Accrued compensation and related benefits | -6,086 |
| Accrued expenses and other current liabilities | 1,519 |
| Accrued warranty liability | -564 |
| Deferred revenue | 604 |
| Operating lease liabilities | -1,913 |
| Accrued interest | -2,695 |
| Net cash used in operating activities | -46,327 |
| Purchases of property and equipment | 798 |
| Purchases of investment securities | 221,969 |
| Sales and maturities of investment securities | 125,083 |
| Net cash (used in) provided by investing activities | -97,684 |
| Proceeds from stock option exercises and espp purchases | 639 |
| Proceeds from issuance of term loans, net of issuance costs | 98,270 |
| Repayment of term loan and extinguishment costs | 204,954 |
| Proceeds from issuance of series a convertible preferred stock, net of issuance costs | 161,548 |
| Payment of deferred financing costs | 0 |
| Net cash provided by financing activities | 55,503 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -88,508 |
| Cash and cash equivalents at beginning of period | 127,343 |
| Cash and cash equivalents at end of period | 38,835 |
Outset Medical, Inc. (OM)
Outset Medical, Inc. (OM)